[A20-10] Siponimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 20.08.2020
Commission awarded on 05.02.2020 by the Federal Joint Committee (G-BA).
Head and nerves
Adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity
Added benefit neither proven for patients with superimposed relapses nor for patients without superimposed relapses.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-51||Siponimod (multiple sclerosis) - Addendum to Commission A20-10||Commission completed|